Real-world data on the incidence and risk of Guillain–Barré syndrome following SARS-CoV-2 vaccination: a prospective surveillance study

[1]  N. Antonio-Villa,et al.  Incidence of Guillain–Barré syndrome following SARS‐CoV‐2 immunization: Analysis of a nationwide registry of recipients of 81 million doses of seven vaccines , 2022, European journal of neurology.

[2]  T. Gonen,et al.  Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose , 2022, Nature Immunology.

[3]  Kensuke Takahashi,et al.  Guillain-Barré Syndrome After BNT162b2 (Pfizer-BioNTec) Vaccination. , 2022, QJM : monthly journal of the Association of Physicians.

[4]  V. Jaiswal,et al.  Guillain‐Barré syndrome after mRNA‐1273 (Moderna) COVID‐19 vaccination: A case report , 2022, Clinical case reports.

[5]  P. Dormitzer,et al.  Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine , 2022, The New England journal of medicine.

[6]  D. Montefiori,et al.  Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial , 2022, Nature Medicine.

[7]  Michael John Smith,et al.  Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. , 2022, JAMA.

[8]  M. Lunn,et al.  COVID-19 vaccination and Guillain-Barré syndrome: analyses using the National Immunoglobulin Database , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

[9]  A. Bertoletti,et al.  Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients , 2021, Med.

[10]  OUP accepted manuscript , 2022, Brain.

[11]  Yoon-Ho Hong,et al.  Guillain–Barré Syndrome and Variants Following COVID-19 Vaccination: Report of 13 Cases , 2022, Frontiers in Neurology.

[12]  Stanley Xu,et al.  Guillain-Barre Syndrome after COVID-19 Vaccination in the Vaccine Safety Datalink , 2021, medRxiv.

[13]  H. Eom,et al.  Guillain-Barré syndrome after vaccination against COVID-19 , 2021, The Lancet Neurology.

[14]  P. Lanteri,et al.  Global, regional, and national burden of Guillain–Barré syndrome and its underlying causes from 1990 to 2019 , 2021, Journal of Neuroinflammation.

[15]  K. Khunti,et al.  Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection , 2021, Nature Medicine.

[16]  J. Nelson,et al.  Surveillance for Adverse Events After COVID-19 mRNA Vaccination. , 2021, JAMA.

[17]  Nguyen H. Tran,et al.  Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) , 2021, The Lancet.

[18]  J. Münch,et al.  Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination , 2021, Nature Medicine.

[19]  P. Tighe,et al.  Guillain–Barré Syndrome Variant Occurring after SARS‐CoV‐2 Vaccination , 2021, Annals of neurology.

[20]  H. Mangat,et al.  Guillain‐Barré Syndrome following ChAdOx1‐S/nCoV‐19 Vaccine , 2021, Annals of neurology.

[21]  E. Woo,et al.  US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021. , 2021, JAMA.

[22]  Andreas Greinacher,et al.  Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination , 2021, The New England journal of medicine.

[23]  J. Gee,et al.  Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines. , 2021, JAMA.

[24]  Hannah Ritchie,et al.  A global database of COVID-19 vaccinations , 2021, Nature Human Behaviour.

[25]  P. Espinosa,et al.  Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine , 2021, Cureus.

[26]  S. Ousman,et al.  The Neuroimmunology of Guillain-Barré Syndrome and the Potential Role of an Aging Immune System , 2021, Frontiers in Aging Neuroscience.

[27]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[28]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[29]  Nguyen H. Tran,et al.  T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial , 2020, Nature Medicine.

[30]  P. Dormitzer,et al.  COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses , 2020, Nature.

[31]  F. Ma,et al.  Vaccines and the risk of Guillain-Barré syndrome , 2019, European Journal of Epidemiology.

[32]  Badrul Islam,et al.  Diagnosis and management of Guillain–Barré syndrome in ten steps , 2019, Nature Reviews Neurology.

[33]  P. G. Ortega,et al.  Guillain-Barré syndrome and influenza vaccines: current evidence , 2019, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.

[34]  G. Marfia,et al.  Regional variation of Guillain-Barré syndrome , 2018, Brain : a journal of neurology.

[35]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[36]  P. Rautava,et al.  Epidemiology of Guillain‐Barré syndrome in Finland 2004–2014 , 2017, Journal of the peripheral nervous system : JPNS.

[37]  T. Jin,et al.  Circulating memory T follicular helper subsets, Tfh2 and Tfh17, participate in the pathogenesis of Guillain-Barré syndrome , 2016, Scientific Reports.

[38]  A. Carvajal,et al.  Guillain-Barré syndrome and influenza vaccines: A meta-analysis. , 2015, Vaccine.

[39]  Chin-Li Lu,et al.  A 15-Year Nationwide Epidemiological Analysis of Guillain-Barré Syndrome in Taiwan , 2015, Neuroepidemiology.

[40]  H. Hartung,et al.  Risk of Guillain–Barré syndrome following pandemic influenza A(H1N1) 2009 vaccination in Germany , 2014, Pharmacoepidemiology and drug safety.

[41]  D. Orlikowski,et al.  Electrophysiological diagnosis of Guillain–Barré syndrome subtype: could a single study suffice? , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[42]  M. Proschan,et al.  Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis , 2013, The Lancet.

[43]  Matthew Wise,et al.  Population Incidence of Guillain-Barré Syndrome: A Systematic Review and Meta-Analysis , 2011, Neuroepidemiology.

[44]  J. Sejvar,et al.  Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. , 2011, Vaccine.

[45]  H. Hartung,et al.  Guillain-Barré syndrome after exposure to influenza virus. , 2010, The Lancet. Infectious diseases.

[46]  J. Sejvar,et al.  Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data. , 2007, Vaccine.

[47]  N. Thomas.  Diagnosis and management of Guillain–Barré syndrome , 2005 .

[48]  C. Koh,et al.  Elevated serum levels of IFN-γ, IL-4 and TNF-α/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stage , 1998, Journal of Neuroimmunology.

[49]  C. Koh,et al.  Elevated serum levels of IFN-gamma, IL-4 and TNF-alpha/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stage. , 1998, Journal of neuroimmunology.

[50]  E. Feuer,et al.  Confidence intervals for directly standardized rates: a method based on the gamma distribution. , 1997, Statistics in medicine.

[51]  D. C. Henckel,et al.  Case report. , 1995, Journal.

[52]  D. Cornblath,et al.  Assessment of current diagnostic criteria for Guillain‐Barré syndrome , 1990, Annals of neurology.

[53]  J. Marks,et al.  Guillain-Barré syndrome in recipients of A/New Jersey influenza vaccine. , 1980, JAMA.